Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Nordic Stocks: Elektrobit, Electrolux, Finnair, NeuroSearch

The Stoxx Nordic 30 Index, the benchmark measure for the region, fell 0.6 percent to 7,595.92 in Stockholm. The index gained 30 percent in 2010, its second-best year since 1999, beaten only by last year’s 38 percent advance.

The OMX Stockholm 30 Index fell 0.8 percent and the OMX Helsinki 25 Index declined 0.6 percent. Norway’s OBX Index and the Copenhagen 20 Index both lost 0.5 percent.

The following shares were among the most active in Nordic markets today. Symbols are in parentheses.

Electrolux AB (ELUXB SS) fell for the first day this week, losing 1.9 percent to 191 kronor. The shares of the Swedish maker of home appliances were downgraded to “sell” from “reduce” at AlphaValue, according to Bloomberg Data.

Elektrobit Oyj (EBC1V FH) fell 4.3 percent to 0.67 euros, its lowest close since November 2009. The Finnish maker of software and hardware that cut jobs this month said it will have a operating loss of as much as 20 million euros ($26 million) in the second-half of 2010. The loss includes impairments recorded after its customer TerraStar Networks Inc. filed for reorganization.

Finnair Oyj (FIA1S FH) rose for a fourth day, adding 0.8 percent to 5.04 euros. Finland’s biggest airline said it is expanding Asian operations by adding flights to Osaka in Japan.

NeuroSearch A/S (NEUR DC) rose for a third day, gaining 3.3 percent to 95 kroner. The Danish medicine developer said results of a meta-analysis of its Huntexil treatment for Huntington’s disease support the conclusions drawn from previous individual trials. The company will now to present and discuss the Huntexil data with regulators during the first half of 2011.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.